Related Experiment Video
Updated: Oct 22, 2025
Using a Chemical Biopsy for Graft Quality Assessment
Published on: June 17, 2020
Mitochondrial DNA may act as a biomarker to predict donor-kidney quality
Changzhen Hao1,2, Jiandong Zhang1,2, Feilong Zhang1,2
1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Abstract:
Kidney transplantation is the best therapy for end-stage renal disease. Demand for kidney transplantation rises year-on-year, and the gap between kidney supply and demand remains large. To meet this clinical need, a gradual expansion in the supply of donors is required. However, clinics lack appropriate tools capable of quickly and accurately predicting post-transplant renal allograft function, and thus assess donor-kidney quality before transplantation. Mitochondrial DNA (mtDNA) is a key component of damage-associated molecular patterns (DAMPs) and plays an important part in ischemia-reperfusion injury (IRI), accelerating the progression of IRI by inducing inflammation and type I interferon responses. mtDNA is known to be closely involved in delayed graft function (DGF) and acute kidney injury (AKI) after transplantation. Thus, mtDNA is a potential biomarker able to predict post-transplant renal allograft function. This review summarizes mtDNA biology, the role mtDNA plays in renal transplantation, outlines advances in detecting mtDNA, and details mtDNA's able to predict post-transplant renal allograft function. We aim to elucidate the potential value of mtDNA as a biomarker in the prediction of IRI, and eventually provide help for predicting donor-kidney quality.
Insights
Mitochondrial DNA (mtDNA) shows promise as a biomarker for predicting kidney transplant success. Early detection of mtDNA could improve donor kidney assessment and reduce transplant complications like delayed graft function.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Kidney transplantation is the optimal treatment for end-stage renal disease, but donor organ shortage persists.
- Accurate prediction of post-transplant graft function is crucial for assessing donor kidney quality.
- Ischemia-reperfusion injury (IRI) significantly impacts graft outcomes, and its mechanisms are not fully understood.
Purpose of the Study:
- To review the biological role of mitochondrial DNA (mtDNA) in renal transplantation.
- To explore the potential of mtDNA as a biomarker for predicting post-transplant renal allograft function.
- To summarize advances in mtDNA detection methods and their application in transplantation.
Main Methods:
- Literature review focusing on mtDNA biology, IRI, and kidney transplantation.
- Analysis of studies investigating mtDNA as a biomarker for graft function.
- Synthesis of current knowledge on mtDNA detection techniques.
Main Results:
- Mitochondrial DNA (mtDNA) acts as a damage-associated molecular pattern (DAMP) involved in IRI.
- mtDNA release is associated with inflammation and type I interferon responses, contributing to IRI.
- mtDNA levels correlate with delayed graft function (DGF) and acute kidney injury (AKI) post-transplantation.
Conclusions:
- Mitochondrial DNA (mtDNA) holds significant potential as a predictive biomarker for renal allograft function.
- Utilizing mtDNA could enhance the assessment of donor kidney quality and improve transplant outcomes.
- Further research into mtDNA detection and its clinical application is warranted to aid in predicting IRI and donor kidney viability.
Related Concept Videos
02:59Animal Mitochondrial Genetics
01:28Kidney Transplant I: Introduction